血清CEA和LDH对肺腺癌靶向治疗疗效和预后的评价作用

目的分析治疗前血清癌胚抗原(CEA)和乳酸脱氢酶(LDH)对接受酪氨酸激酶抑制剂(TKIs)靶向治疗的肺腺癌患者疗效和预后的评价作用。方法回顾性收集45例接受表皮生长因子受体(EGFR)TKIs治疗的肺腺癌患者的完整临床资料,分析CEA、LDH与EGFR-TKI治疗疗效和无进展生存期(PFS)的关系。结果以正常值为截点,治疗前血清CEA值正常9例,升高36例,两组控制率分别为44.4%、83.3%,差异有统计学意义(P=0.028)。治疗前血清LDH是否升高与治疗疗效无显著影响(P0.05)。生存分析结果显示:治疗前CEA值升高、EGFR突变患者的中位PFS显著延长(P=0.010、0.005),EGFR突变状态、治疗前LDH水平是影响患者PFS的独立因素(P=0.009、0.017)。结论治疗前血清CEA、LDH水平对肺腺癌TKIs靶向治疗患者的疗效和预后的评估有重要的参考价值。

Predictive and prognostic significance of CEA and LDH in lung adenocarcinoma patients receiving targeted therapy

Objective To investigate the predictive and prognostic significance of CEA and LDH in lung ad-enocarcinoma patients receiving targeted therapy with TKIs. Methods The clinical data of 45 lung adenocarcinoma patients treated with epidermal growth factor receptor tyrosine-kinase inhibitor ( EGFR-TKI) were collected, their ser-um CEA and LDH levels were detected to evaluate efficacy and prognosis. Results Taking normal value as the cut-off point, the level of serum CEA was normal in 9 cases and increased in 36 cases, and the control rate was 44. 4%and 83. 3% (P=0. 028). There was no significant correlation between pre-treatment serum LDH and the therapeutic effect (P>0. 05). Survival analysis showed that patients with high pre-treatment serum levels of CEA and EGFR mutation had longer mPFS (P=0. 010, 0. 005). Multivariate cox regression analysis showed that EGFR mutation status and LDH levels before treatment were both independent factors for PFS (P=0. 009, 0. 017). Conclusion The pre-treatment serum levels of CEA and LDH may have important clinical significance for prediction the efficacy and prognosis in lung adenocarcinoma patients receiving targeted therapy with EGFR-TKI.